Creo Medical Group (LON:CREO) Insider Craig Jonathan Gulliford Acquires 6,250 Shares

Creo Medical Group PLC (LON:CREO) insider Craig Jonathan Gulliford purchased 6,250 shares of Creo Medical Group stock in a transaction on Wednesday, July 1st. The stock was bought at an average price of GBX 14 per share, with a total value of £875.

Creo Medical Group Stock Performance

Shares of CREO stock traded up GBX 0.01 during trading hours on Monday, reaching GBX 14.57. 1,405,552 shares of the company traded hands, compared to its average volume of 871,779. The firm has a 50-day moving average price of GBX 13.18 and a 200 day moving average price of GBX 12.90. The company has a market cap of £70.81 million, a P/E ratio of 14.57 and a beta of 1.62. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19. Creo Medical Group PLC has a 12-month low of GBX 9.52 and a 12-month high of GBX 18.50.

Creo Medical Group (LON:CREO) last released its earnings results on Friday, May 22nd. The company reported GBX (0.04) earnings per share (EPS) for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.The firm had revenue of GBX 600 million during the quarter. As a group, sell-side analysts predict that Creo Medical Group PLC will post -10.0800005 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group restated a “house stock” rating and set a GBX 40 price objective on shares of Creo Medical Group in a research report on Monday, June 29th.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.